Clinical trials: Diseases of Aortic Valve
Aortic Stenosis, Myocardial Fibrosis
Mechanism of Decompensation Evaluation - Aortic Stenosis
Aortic stenosis is the most common heart valve disease requiring intervention in high income countries. It is characterised by progressive valvular thickening, and restriction as well is hypertrophy and fibrosis of the left…
- Conditions
- Aortic Stenosis, Myocardial Fibrosis, Left Ventricular Hypertrophy
- Trial name
- MODE-AS (NCT03332745)
- Where
- United Kingdom
- Volunteers
- 90 people
- Sponsor
- University of Edinburgh
Aortic Regurgitation, Transcatheter Aortic Valve Replacement (TAVR)
TAVR for Aortic Regurgitation Under TTE Guidance
Transcatheter aortic valve replacement (TAVR) is an established therapy for severe aortic valve disease, yet conventional workflows rely on fluoroscopy and iodinated contrast, exposing patients and operators to ionizing radiation…
- Trial name
- NCT07458672
- Testing
- TTE guided TAVR
- Volunteers
- 30 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Aortic Stenosis
AntiCoagulation Versus AcetylSalicylic Acid After Transcatheter Aortic Valve Implantation
ACASA-TAVI is a pragmatic randomized controlled trial assessing the value of anticoagulation therapy versus the standard antiplatelet therapy after transcatheter aortic valve implantation in patients with aortic stenosis.
- Trial name
- ACASA-TAVI (NCT05035277)
- Testing
- Acetylsalicylic acid, Apixaban, Rivaroxaban
- Where
- 3 sites in Norway
- Volunteers
- 360 people
- Sponsor
- Oslo University Hospital
Aortic Stenosis
PERIGON Pivotal Trial
To evaluate the safety and effectiveness of the Model 400 aortic valve bioprosthesis.
- Trial name
- PERIGON (NCT02088554)
- Testing
- Model 400 aortic valve bioprosthesis
- Where
- 38 sites in United States, Canada and 6 more
- Volunteers
- 1,312 people
- Sponsor
- Medtronic Cardiac Surgery
Severe Aortic Valve Stenosis, Aortic Valve Stenosis
Single Antiplatelet Treatment With Ticagrelor or Aspirin After Transcatheter Aortic Valve Implantation
The optimal pharmacological therapy after transcatheter aortic valve implantation (TAVI) to prevent valve thrombosis and reduce thromboembolic complications without significantly increasing the risk of bleeding is not yet fully…
- Conditions
- Severe Aortic Valve Stenosis, Aortic Valve Stenosis, Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Aortic Valve Implantation (TAVI)
- Trial name
- REAC-TAVI2 (NCT05283356)
- Testing
- Ticagrelor 60mg
- Where
- Spain
- Volunteers
- 1,206 people
- Sponsor
- Fundacin Biomedica Galicia Sur
Aortic Valve Stenosis
Non-Contrast Magnetic Resonance Angiography Assessment of Patients Referred for Transcatheter Aortic Valve Implantation
The overall objective of this proposal is to examine the feasibility and accuracy of non-contrast magnetic resonance angiography (MRA) to comprehensively evaluate individuals referred for transcatheter aortic valve implantation…
- Trial name
- NCT02007967
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Michigan
Trans Catheter Aortic Valve, Aortic Stenosis
Functional and Quality of Life Improvement Following Transcatheter Heart Valve Implantation
The objective is to observe trends in patient characteristics and outcomes after aortic or mitral transcatheter heart valve replacement over time.
- Trial name
- NCT02023060
- Where
- 5 sites in Israel
- Volunteers
- 100 people
- Sponsor
- Sheba Medical Center
Heart Septal Defects, Ventricular, Aortic Valve Insufficiency
Aortic Regurgitation After Surgical Repair of Outlet-Type Ventricular Septal Defect
The major risk factors of aortic valve replacement in three outlet types VSD after surgical repair were the severity of preoperative AR and older operation age.
- Trial name
- NCT00173186
- Where
- Taiwan
- Volunteers
- 411 people
- Sponsor
- National Taiwan University Hospital
Severe Aortic Stenosis
Transfemoral TAVI With or Without Coronary Angiogram in Patients With Severe Aortic Stenosis (PURE TAVI)
This study will be conducted in patients with severe aortic stenosis who are referred for transcatheter aortic valve implantation (TAVI). TAVI is the recommended treatment for severe aortic stenosis.
- Trial name
- PURETAVI (NCT06898086)
- Testing
- Transcatheter aortic valve implantation
- Where
- 23 sites in Austria, Czechia and 5 more
- Volunteers
- 620 people
- Sponsor
- Rede Optimus Hospitalar SA
Hypertrophic Cardiomyopathy
3D Non-invasive Myocardial Electrical Propagation Mapping as a New Tool to Predict Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is very common. The thickened heart muscle can disrupt the normal functioning of the heart's electrical system, resulting in fast or irregular heartbeats.
- Trial name
- 3D-CMH (NCT03550573)
- Testing
- CardioInsight™ Noninvasive 3D Mapping System
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Hospices Civils de Lyon
Aortic Valve Stenosis, Aortic Valve Insufficiency
Avalus European Registry - an Observational Study to Evaluate Safety and Efficacy in a Real World Population
This is a prospective, observational, single-arm, multi-center registry of patients undergoing bioprosthetic aortic valve replacement with the Avalus valve.
- Trial name
- Avalus (NCT05572710)
- Where
- 19 sites in Belgium, Denmark and 6 more
- Volunteers
- 1,000 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Hypertrophic Cardiomyopathy
Study of Hypertrophic Cardiomyopathy Under Stress Conditions. Concordance Between Two Complementary Tests: Stress MRI and Exercice Stress Echocardiography
Hypertrophic cardiomyopathy (HCM) is a primitive myocardic disease and the first of genetic cardiac diseases. The definition of HCM is an increase of the myocardial thickness of the left ventricle (LV) wall without any other…
- Trial name
- CMHStress (NCT02500420)
- Testing
- Diagnosis examens
- Where
- France
- Volunteers
- 25 people
- Sponsor
- University Hospital, Montpellier
Aortic Valve Regurgitation, Aortic Valve Disease Mixed
JOURNEY LVAD: JOURNEY Left Ventricular Assist Device
The objective of this study is to assess the safety and effectiveness of the J-Valve Transfemoral Transcatheter Heart Valve System in patients on left ventricular assist device (LVAD) support with significant native aortic valve…
- Conditions
- Aortic Valve Regurgitation, Aortic Valve Disease Mixed, Aortic Insufficiency
- Trial name
- NCT07363473
- Testing
- J-Valve Transfemoral System
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- JC Medical, Inc., an affiliate of Edwards Lifesciences LLC
Aortic Valve Stenosis
Impact of Local Tissue Inflammation on Intramyocardial Conduction Pathways Post Percutaneous Valve : Evaluation by Positron Emission Tomography on Exploratory Cohort
Aortic valve stenosis is the most common valve disease leading to surgical or percutaneous intervention in Europe and North America.
- Trial name
- IMPACT (NCT05308888)
- Testing
- 18F-FDG PET-CT
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Brest
Aortic Valve Stenosis, Aortic Valve Failure
Portico Valve-in-Valve Retrospective Registry
The objective of this data-collection study is to retrospectively evaluate the safety and clinical performance of the Portico transthoracic aortic valve for Valve-in-Valve treatment of a failed aortic surgical bioprosthetic valve…
- Conditions
- Aortic Valve Stenosis, Aortic Valve Failure, Aortic Insufficiency, Aortic Stenosis
- Trial name
- NCT05002088
- Testing
- Transcatheter Aortic Valve Replacement
- Where
- 7 sites in Australia, Denmark and 2 more
- Volunteers
- 71 people
- Sponsor
- Abbott Medical Devices
Cardiovascular Diseases
SAVR: IMPACT of Pre-existing Comorbidities on Patient Outcomes and Prosthetic Valve Performance in a Real-world Setting.
The IMPACT Registry represents a non-interventional, prospective, open-label, multicenter, international registry with a follow-up of 5 years that includes data of patients undergoing aortic valve replacement with the Edwards…
- Trial name
- IMPACT (NCT04053088)
- Testing
- INSPIRIS RESILIA Aortic Valve™
- Where
- 22 sites in Austria, Germany and 2 more
- Volunteers
- 500 people
- Sponsor
- Institut für Pharmakologie und Präventive Medizin
Ischemic Cardiomyopathy, Dilated Cardiomyopathy
Manganese-Enhanced Magnetic Resonance Imaging of the Myocardium
Scanning the heart using magnetic resonance imaging (MRI) enables detailed assessment of its structure and function. MRI can give more detailed information about the heart by using a contrast 'dye' that is injected into a vein…
- Conditions
- Ischemic Cardiomyopathy, Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy
- Trial name
- NCT03607669
- Testing
- Mangafodipir trisodium
- Where
- United Kingdom
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University of Edinburgh
Aortic Stenosis, TAVI(Transcatheter Aortic Valve Implantation)
Non-antithrombotic Therapy After Transcatheter Aortic Valve Implantation Trial
Aspirin group: Aspirin 100mg will be started within 24 hours after randomization, and continued aspirin 100mg/day the end of the study period.
- Conditions
- Aortic Stenosis, TAVI(Transcatheter Aortic Valve Implantation), Aspirin, DAPT(Dual Antiplatelet Therapy)
- Trial name
- NCT06007222
- Testing
- Aspirin group, Non-antithrombotic group
- Where
- Japan
- Volunteers
- 400 people
- Sponsor
- OCEAN-SHD Study Group
Aortic Valve Stenosis
Metabolic Determinants of the Progression of Aortic Stenosis
Calcific aortic stenosis (AS) has become the most common cardiac disease after coronary artery disease and hypertension. Unfortunately no medical therapies have been proven to decrease either the progression of valve stenosis or…
- Trial name
- PROGRESSA (NCT01679431)
- Testing
- Doppler-echocardiography, Computed tomography, Magnetic resonance imaging
- Where
- Canada
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Laval University
HCM - Hypertrophic Cardiomyopathy
Effect of Henagliflozin on Myocardial Fibrosis in Non-Obstructive HCM: A Randomized, Double-Blind, Placebo-Controlled Trial Using 68Ga/18F-FAPI PET/CMR
his is a single-center, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effect of Henagliflozin (an SGLT2 inhibitor) on myocardial fibrosis burden in patients with non-obstructive hypertrophic…
- Trial name
- NCT07294495
- Testing
- Henagliflozin (SGLT2 Inhibitor)
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Shanghai East Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.